Dr. Leo Grady is the new CEO of Paige. AI, a healthcare analytics startup that uses artificial intelligence and machine learning in the diagnosis and treatment of diseases like cancer.
Grady’s appointment was announced in this report from Tech Observer:
Grady has more than 15 years of experience in prototyping, developing, and bringing to market some of the industry’s most advanced machine learning, computer vision, and medical imaging technologies and products. Prior to joining Paige.AI, Grady was Senior Vice President of Engineering for HeartFlow, a leading medical technology company recently valued at more than $1.5 billion, that leverages deep learning to transform the way cardiac disease is diagnosed and treated.
Paige.AI was launched in 2018 based on technology developed by its Co-Founder and Chief Scientific Officer, Dr. Thomas Fuchs, and a license agreement with Memorial Sloan Kettering Cancer Center (MSK). Paige.AI is well on its way to digitizing five million pathology slides from MSK’s enormous archive, giving the company an unparalleled database on which to build its AI. In its first year, Paige.AI has hired an outstanding group of AI scientists and software engineers who are working to create fundamental advances in computational pathology, initially focused on developing a full suite of modules and products to serve the needs of diagnostic pathologists around the world.
“The Board is thrilled to welcome Leo to the Paige.AI team as our new CEO,” said Jim Breyer, CEO of Breyer Capital, a premier global venture capital firm and a lead Paige.AI investor. “Leo is an accomplished healthcare technology executive who has successfully led the development and commercialization of transformative technologies rooted in medical imaging and machine learning. With those strong credentials in both the business and scientific arenas, Leo is highly regarded and ideally positioned to help build on Paige.AI’s uniquely compelling foundation of world-class AI, data at scale, and excellent clinical expertise.”
